"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 7 | 0 | 7 |
| 2011 | 1 | 3 | 4 |
| 2012 | 4 | 1 | 5 |
| 2013 | 3 | 0 | 3 |
| 2014 | 5 | 1 | 6 |
| 2015 | 4 | 2 | 6 |
| 2016 | 4 | 4 | 8 |
| 2017 | 5 | 4 | 9 |
| 2018 | 2 | 4 | 6 |
| 2019 | 4 | 2 | 6 |
| 2020 | 7 | 5 | 12 |
| 2021 | 7 | 2 | 9 |
| 2022 | 2 | 1 | 3 |
| 2023 | 8 | 0 | 8 |
| 2024 | 4 | 4 | 8 |
| 2025 | 4 | 3 | 7 |
| 2026 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Evaluating time to treatment intensification among drug na?ve type 2 diabetes patients: a comparison of initial combination therapy vs step-therapy approaches. Curr Med Res Opin. 2026 Apr; 42(4):699-711.
-
Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Medicine (Baltimore). 2026 May 29; 105(22):e49050.
-
Geroprotective effects of diet and exercise plus metformin in frail older veterans with obesity: The DEMFOS randomized trial protocol. Contemp Clin Trials. 2026 Jun; 165:108321.
-
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026 Mar 27; 17(1):78-89.
-
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026 Feb 01; 49(2):325-334.
-
Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025 09 01; 185(9):1092-1101.
-
Low-dose metformin requires brain Rap1 for its antidiabetic action. Sci Adv. 2025 Aug; 11(31):eadu3700.
-
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis. Nature. 2025 06; 642(8067):431-441.
-
Semaglutide Plus Metformin Versus Metformin Alone For Antipsychotic-Induced Weight Gain In Patients With Type 2 Diabetes Mellitus. Psychiatr Q. 2025 12; 96(4):819-827.
-
Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.